BridgeBio Pharma, Inc. (BBIO)
NASDAQ · Healthcare
BridgeBio Pharma, Inc. Operating Income 2019–2025
BridgeBio Pharma, Inc. annual/quarterly operating income history and growth rate from 2019 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- BridgeBio Pharma, Inc. operating income for the quarter ending March 31, 2026 was -106.0 M, a 1.52% increase year-over-year.
- BridgeBio Pharma, Inc. operating income for the twelve months ending March 31, 2026 was -489.8 M, a 6.64% decrease year-over-year.
- BridgeBio Pharma, Inc. annual operating income for 2025 was -523.4 M, a 11.73% decrease from 2024.
- BridgeBio Pharma, Inc. annual operating income for 2024 was -593.0 M, a 2.37% decrease from 2023.
- BridgeBio Pharma, Inc. annual operating income for 2023 was -607.4 M, a 18.58% increase from 2022.
- BridgeBio Pharma, Inc. annual operating income for 2022 was -512.2 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
BridgeBio Pharma, Inc. Operating Income — FAQ
BridgeBio Pharma, Inc. (BBIO) operating income over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
What is BridgeBio Pharma, Inc.'s operating income?
BridgeBio Pharma, Inc. (BBIO) reported operating income of -$523M for fiscal 2025.
Where can I see BBIO's operating income history?
The chart and table above show BridgeBio Pharma, Inc.'s operating income by year and by quarter, including the growth rate.